The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Promising therapies under investigation in AL amyloidosis: IMiDs & bispecific antibodies
Patrick Hagen, MD, Loyola University Medical Center, Chicago, IL, gives an overview of current therapies under investigation for the treatment of light chain (AL) amyloidosis. Drug discovery across various plasma cell disorders has provided new treatments for AL amyloidosis, including novel immunomodulatory drugs (IMiDs) and bispecific antibodies. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau Sanofi
